Last reviewed · How we verify
ADX-629
At a glance
| Generic name | ADX-629 |
|---|---|
| Also known as | Open label |
| Sponsor | Aldeyra Therapeutics, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- ADX-629 Therapy for Sjogren-Larsson Syndrome (PHASE1, PHASE2)
- A Clinical Trial Investigating the Safety and Efficacy of Subjects With Alcohol Associated Hepatitis (Part 1) (PHASE2)
- A Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Subjects With Plaque Psoriasis (PHASE2)
- A Clinical Trial to Evaluate the Safety and Efficacy in Subjects With Chronic Cough (PHASE2)
- A Clinical Trial to Evaluate the Safety and Efficacy of ADX-629 in in Subjects With Elevated Ethanol Levels (PHASE1, PHASE2)
- A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacodynamics for the Treatment of COVID-19. (PHASE2)
- A Double Masked, Placebo Controlled, Single Center, Randomized Clinical Trial to Assess the Safety and Efficacy of Subjects With Mild Asthma Induced by the Bronchial Allergen Challenge (BAC) (PHASE2)
- A Clinical Trial in Subjects With Atopic Dermatitis (Part 1) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ADX-629 CI brief — competitive landscape report
- ADX-629 updates RSS · CI watch RSS
- Aldeyra Therapeutics, Inc. portfolio CI